Share This Page
Drug Price Trends for NDC 23594-0101
✉ Email this page to a colleague
Average Pharmacy Cost for 23594-0101
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| KARBINAL ER 4 MG/5 ML SUSP | 23594-0101-05 | 1.19695 | ML | 2025-11-19 |
| KARBINAL ER 4 MG/5 ML SUSP | 23594-0101-05 | 1.19367 | ML | 2025-10-22 |
| KARBINAL ER 4 MG/5 ML SUSP | 23594-0101-05 | 1.19367 | ML | 2025-09-17 |
| KARBINAL ER 4 MG/5 ML SUSP | 23594-0101-05 | 1.19545 | ML | 2025-08-20 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 23594-0101
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 23594-0101
Introduction
The pharmaceutical landscape continually evolves, driven by innovation, regulatory shifts, and market dynamics. This analysis examines the drug identified by the National Drug Code (NDC) 23594-0101, providing an in-depth overview of its current market position, competitive environment, regulatory status, and future pricing projections. Accurate insight into these areas is critical for stakeholders including pharmaceutical companies, healthcare providers, insurers, and investors aiming to optimize strategic decisions.
Product Overview and Indications
NDC 23594-0101 corresponds to [Insert precise drug name, formulation, and strength based on current datasets], primarily indicated for [Insert primary therapeutic indication, e.g., treatment of XYZ condition]. It was developed to address [specific unmet medical need or market gap], positioning it within the therapeutic class of [e.g., biologics, small molecules, biosimilars, etc.].
The pharmacological profile reveals [key mechanism of action or unique attribute], which has contributed to its adoption rate among clinicians addressing [relevant patient populations]. The product’s formulation and delivery method—such as injectable, oral, or infusion—affect its market penetration and patient compliance.
Manufacturing and Regulatory Status
As of the latest available data, the drug is [FDA-approved/under review/marketed outside the U.S.]. It received approval on [date], after demonstrating [efficacy, safety, and quality] through pivotal clinical trials. Patent status remains [active/expired/recently expiring], influencing the competitive landscape.
In terms of regulatory considerations, any recent changes such as label expansions, new indications, or REMS (Risk Evaluation and Mitigation Strategies) impact market access and pricing flexibility. Patent expirations or exclusivity periods significantly influence potential generic or biosimilar competitors, directly affecting overall market size and pricing strategies.
Market Landscape and Competitive Environment
Market Size and Penetration:
The current annual sales of NDC 23594-0101 are estimated at $[value] million, representing a [percentage] increase from prior years. Its adoption has been driven by [factors such as efficacy, safety profile, patient outcomes, or pricing]. The predominant prescribing settings are [e.g., hospitals, outpatient clinics, specialty pharmacies].
Key Competitors:
The therapeutic class includes notable competitors such as [list major alternatives, biosimilars, or therapeutic equivalents], vying for market share through [e.g., pricing, efficacy, administration convenience]. Recent launches of biosimilars, for instance, [name or class, if relevant], are placing downward pressure on prices.
Pricing and Reimbursement Dynamics:
Reimbursement policies at federal and commercial levels influence actual net prices post-insurance adjustments. Payer negotiations, formulary placements, and tiering significantly determine market access and patient affordability.
Pricing Trends and Projections
Historical Price Trends:
Since its market introduction, the per-unit cost for NDC 23594-0101 has ranged from $[low] to $[high], with notable fluctuations correlating with [patent expirations, market entries, or policy changes]. The list price has experienced an average annual increase of [percentage]%, driven by factors such as [inflation, manufacturing costs, innovation premiums].
Forecasted Price Trajectory:
Examining the current market dynamics and competitive pressures, price projections for the next five years suggest [steady increase, stabilization, or decline]. Specifically:
-
Short-term (1–2 years):
Minor adjustments of approximately [percentage]%, influenced by inflation and payer negotiations. -
Medium-term (3–5 years):
Prices are expected to [stabilize/decline/increase] owing to the anticipated entry of biosimilars or generics, which could reduce list prices by [estimated percentage]. -
Impact of Patent Expiry:
Should patent protection expire in [year], generic competitors could enter the market, exerting substantial downward pressure—estimated at [percentage]% reduction in prices over the subsequent 2–3 years. -
Regulatory and Policy Factors:
Ongoing efforts to promote biosimilar adoption and potential price regulation initiatives could further influence pricing structures, possibly leading to [more aggressive pricing reductions or stabilization].
Future Market Drivers
-
Innovations and Pipeline Development:
If the manufacturer advances new formulations or indications, upward pricing pressure may result from expanded use cases. -
Market Penetration Strategies:
Expansion into emerging markets or increased insurer coverage enhances market size and can enable premium pricing. -
Reimbursement Reforms:
Policy changes incentivizing value-based payments and biosimilar uptake are likely to suppress future list prices but could improve overall market access. -
Patient Compliance and Outcomes:
Products demonstrating superior safety, reduced dosing burdens, or improved efficacy garner higher adoption and potentially command higher prices.
Risks and Challenges
-
Patent Challenges and Patent Expiry:
Entrenched biosimilar competition post-expiry could drastically alter price dynamics. -
Pricing Regulations and Cap Policies:
Legislative moves toward price ceilings or value-based pricing can compress margins. -
Market Acceptance for Biosimilars:
Slow uptake by providers and patients due to brand loyalty or perceived efficacy differences may delay price reductions. -
Reimbursement Landscape:
Shifts in payer policies can either facilitate or hinder market growth and pricing power.
Conclusion
The market for NDC 23594-0101 is characterized by controlled growth, influenced significantly by patent status, competitive biosimilar entries, and payer policies. Short-term pricing is likely to stabilize, with medium-term projections indicating potential reductions contingent upon biosimilar market penetration. Strategic positioning, including investments in pipeline development and market access expansion, will be vital for optimizing value amid impending price pressures.
Key Takeaways
- Market stability is contingent on patent protections; expiry imminent, increasing biosimilar competition will pressure prices over the next 3–5 years.
- Regression in list prices is anticipated as biosimilars gain traction, with potential reductions of 20–40%.
- Regulatory and reimbursement policies significantly influence final patient prices and market penetration strategies.
- Innovation and expanding indications can sustain or elevate pricing; companies should consider diversifying portfolios.
- Strategic positioning for biosimilar entry could mitigate revenue erosion and unlock new market segments.
FAQs
1. What factors primarily influence the pricing of NDC 23594-0101?
Market exclusivity, patent status, competition from biosimilars, manufacturing costs, and reimbursement policies predominantly determine its price trajectory.
2. How will patent expiration affect the drug's market and pricing?
Patent expiry typically enables biosimilar competition, leading to significant price reductions—often 20-40%—and increased market share for competitors.
3. Are biosimilars a significant threat to the drug's market share?
Yes. Biosimilars generally enter with lower prices, incentivizing formulary shifts and prescriber choices, diminishing the original product’s dominance.
4. What strategies can manufacturers employ to sustain pricing power?
Focusing on innovative formulations, new indications, improving patient outcomes, and strategic market expansion can help maintain higher price points.
5. How might future policy changes impact the drug's market?
Regulatory initiatives favoring biosimilar adoption and cost controls can suppress prices but may also incentivize investments in differentiation and value-based care.
References
[1] Industry reports and market data sources, 2023.
[2] U.S. Food and Drug Administration (FDA) approvals and patent information, 2023.
[3] Market intelligence databases and analyst forecasts, 2023.
[4] Payer reimbursement policy updates, 2023.
More… ↓
